Since its inception, Oncolytics Biotech has worked to create a worldwide patent portfolio that broadly protects its products and technology. The Company continues to file for new patents to protect new innovations as they are developed. With over four hundred issued patents worldwide, including patents covering REOLYSIN® technology and modified herpes and adenoviruses, Oncolytics has an exceptional proprietary position in the oncolytic virus field.

Issued patent claims pertaining to the reovirus cover areas including:

  • Compositions of matter comprising reovirus
  • Pharmaceutical use of reoviruses to treat neoplasia and cellular proliferative diseases
  • Combination thera py with radiation, chemotherapy and/or immune suppressants
  • Methods for manufacturing reovirus and screening for susceptibility to reovirus
  • Pharmaceutical use of reoviruses in transplantation procedures